RecruitingNCT01408225

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis


Sponsor

Ohio State University Comprehensive Cancer Center

Enrollment

5,000 participants

Start Date

Mar 17, 2011

Study Type

OBSERVATIONAL

Conditions

Summary

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live. * Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups. * Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Diagnosis of a plasma cell dyscrasia

Exclusion Criteria1

  • Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.

Interventions

PROCEDUREtissue banking

tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.


Locations(1)

Ohio State University Medical Center

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01408225


Related Trials